Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

194 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A slow-cycling subpopulation of melanoma cells with highly invasive properties.
Perego M, Maurer M, Wang JX, Shaffer S, Müller AC, Parapatics K, Li L, Hristova D, Shin S, Keeney F, Liu S, Xu X, Raj A, Jensen JK, Bennett KL, Wagner SN, Somasundaram R, Herlyn M. Perego M, et al. Among authors: Bennett KL. Oncogene. 2018 Jan 18;37(3):302-312. doi: 10.1038/onc.2017.341. Epub 2017 Sep 18. Oncogene. 2018. PMID: 28925403 Free PMC article.
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.
Borgdorff V, Rix U, Winter GE, Gridling M, Müller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN. Borgdorff V, et al. Among authors: Bennett KL. Oncogene. 2014 May 8;33(19):2531-9. doi: 10.1038/onc.2013.185. Epub 2013 Jun 3. Oncogene. 2014. PMID: 23728343
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Fauster A, Rebsamen M, Huber KV, Bigenzahn JW, Stukalov A, Lardeau CH, Scorzoni S, Bruckner M, Gridling M, Parapatics K, Colinge J, Bennett KL, Kubicek S, Krautwald S, Linkermann A, Superti-Furga G. Fauster A, et al. Among authors: Bennett KL. Cell Death Dis. 2015 May 21;6(5):e1767. doi: 10.1038/cddis.2015.130. Cell Death Dis. 2015. PMID: 25996294 Free PMC article.
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. Rix U, et al. Among authors: Bennett KL. Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890374
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P. Peter B, et al. Among authors: Bennett KL. Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9. Leukemia. 2016. PMID: 26349526 Free PMC article.
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P. Sillaber C, et al. Among authors: Bennett K. Eur J Clin Invest. 2009 Dec;39(12):1098-109. doi: 10.1111/j.1365-2362.2009.02206.x. Epub 2009 Sep 9. Eur J Clin Invest. 2009. PMID: 19744184
Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function.
Lercher A, Bhattacharya A, Popa AM, Caldera M, Schlapansky MF, Baazim H, Agerer B, Gürtl B, Kosack L, Májek P, Brunner JS, Vitko D, Pinter T, Genger JW, Orlova A, Pikor N, Reil D, Ozsvár-Kozma M, Kalinke U, Ludewig B, Moriggl R, Bennett KL, Menche J, Cheng PN, Schabbauer G, Trauner M, Klavins K, Bergthaler A. Lercher A, et al. Among authors: Bennett KL. Immunity. 2019 Dec 17;51(6):1074-1087.e9. doi: 10.1016/j.immuni.2019.10.014. Epub 2019 Nov 26. Immunity. 2019. PMID: 31784108 Free PMC article.
194 results
Jump to page